PPC
MYGN icon

Park Place Capital’s Myriad Genetics MYGN Stock Holding History

Park Place Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,366
Closed -$21.9K – 966
2023
Q3 		$21.9K Hold
1,366
– – 0.01% 622
2023
Q2 		$31.7K Hold
1,366
– – 0.01% 570
2023
Q1 		$31.7K Hold
1,366
– – 0.01% 562
2022
Q4 		$20K Buy
+1,366
New +$25.5K 0.01% 653

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Park Place Capital's MYGN Position: Q4 2023 in Review

Park Place Capital sold out of Myriad Genetics (MYGN) in Q4 2023, closing a stake of 1,366 shares — an estimated $21.9K sold.

Park Place Capital first reported a position in MYGN in Q4 2022 and held it in 4 quarters. The position peaked at $31.7K in Q1 2023. 194 funds tracked by Wall St. Rank hold MYGN as of Q4 2023.

  • Park Place Capital reported no remaining Myriad Genetics position as of Q4 2023 after selling out during the quarter.
  • Park Place Capital sold 1,366 Myriad Genetics shares in Q4 2023, an estimated $21.9K.
  • Park Place Capital first reported a position in Myriad Genetics in Q4 2022 and held it in 4 quarters.
  • Park Place Capital's Myriad Genetics position peaked at $31.7K in Q1 2023.
  • 194 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2023.

Based on Park Place Capital's 13F filing for Q4 2023, filed 24 Jan 2024.